Insulin Dose and Heart and Kidney Complications in Type 1 Diabetes
Looks at how daily insulin amount relates to complications in people with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Relationship Between Insulin Dose and Complications in Type 1 Diabetes
Key facts
- Where
- Pittsburgh, United StatesSee the site
Where in United States
- University of PittsburghPittsburgh, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rachel Miller
- Trial code
- NCT07911033
- Record updated
- 2 November 2026
- Original description
The goal of this observational study is to better understand how the amount of insulin people with type 1 diabetes are using relates to blood glucose control and the risk of complications. The main questions this study aims to answer are: 1) Is insulin dose related to the long-term risk of developing heart disease, kidney disease and other complications in people with type 1 diabetes, after accounting for blood glucose? and 2) Does insulin dose relate to early signs of heart and kidney disease (i.e., disease that is not clinically detectable) in people with type 1 diabetes who are using modern diabetes management regimens?Read full original descriptionShow less
Insulin Dose and Vascular Complications in Type 1 Diabetes: Its Role Beyond Insulin Resistance and Glycemia
The goal of this observational study is to better understand how the amount of insulin people with type 1 diabetes are using relates to blood glucose control and the risk of complications. The main questions this study aims to answer are: 1) Is insulin dose related to the long-term risk of developing heart disease, kidney disease and other complications in people with type 1 diabetes, after accounting for blood glucose? and 2) Does insulin dose relate to early signs of heart and kidney disease (i.e., disease that is not clinically detectable) in people with type 1 diabetes who are using modern diabetes management regimens?
Inclusion: Study Aim 1 - All existing participants of the Pittsburgh EDC study; Study Aim 2 - Existing participants of the Pittsburgh EDC study who were alive and not withdrawn as of the most recent (2023-24) survey follow-up.
Exclusion: Study Aim 2 - History of major cardiovascular disease, kidney failure, or pancreatic transplant; Study Aim 1 - For each outcome of interest, individuals who already had the outcome at study baseline.